Stephen Hoge - Feb 9, 2023 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role: President
Signature: /s/ Brian Sandstrom, as Attorney-in-Fact
Stock symbol: MRNA
Transactions as of: Feb 9, 2023
Transactions value $: -$40,156
Form type: 4
Date filed: 2/13/2023, 03:14 PM
Previous filing: Nov 30, 2022
Next filing: Mar 2, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MRNA	Common Stock	Options Exercise	$0	+522	+0.03%	$0.00	1.63M	Feb 9, 2023	Direct	F1
transaction	MRNA	Common Stock	Sale	-$40.2K	-245	-0.02%	$163.90	1.63M	Feb 10, 2023	Direct	F2
holding	MRNA	Common Stock						4.12K	Feb 9, 2023	By Valhalla, LLC
holding	MRNA	Common Stock						152K	Feb 9, 2023	By Trust	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MRNA	Restricted Stock Units	Options Exercise	$0	-522	-11.1%	$0.00	4.18K	Feb 9, 2023	Common Stock	522	$0.00	Direct	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock units convert into common stock on a one-for-one basis.
F2	Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
F3	These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F4	25% of the shares subject to this restricted stock unit award vested on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter.